<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sliwa, Karen</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel Biomarkers Aid in Diagnosis of PPCM</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">Peripartum cardiomyopathy (PPCM) is a potentially life-threatening disease that is manifest as heart failure with left ventricular systolic dysfunction that occurs toward the end of pregnancy or in the months following delivery. It is associated with significant mortality and morbidity. Although its etiology has recently been the subject of much study, PPCM remains a diagnosis of exclusion. This article discusses 2 potential biomarkers for PPCM that may improve diagnosis and thus treatment outcomes.</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>